NOVO NORDISK PHARMACEUTICAL INDUSTR supplier risk profile Q1-2026: 164 shipments, 13 suppliers, compliance grade A.
NOVO NORDISK PHARMACEUTICAL INDUSTR imported 164 shipments in Q1 2026 across 13 suppliers spanning 8 countries. Ireland dominated sourcing at 45% of shipments, followed by Denmark at 38%, with West Pharma (Ireland) and Novo Nordisk entities (Denmark) as primary suppliers. The trade footprint concentrated in HS Chapter 90 (optical and medical instruments), which accounted for approximately 57% of documented shipments, alongside chemical and pharmaceutical intermediates across 21 HS codes.
Trigram screen against OFAC SDN, BIS Entity List, UFLPA Entity List, SAM Exclusions, EU FSF, UK HMT, UN SC, and 25+ allied jurisdictions.
Distance-screened against all 380 facilities in the ASPI Xinjiang Data Project. Proximity score: 100 / 100.
The importer recorded zero sanctions watchlist matches and zero suppliers with direct exposure under forced-labor proximity mapping. Compliance screening flagged no secondary-tier concerns across the 38 tier-2 and 169 tier-3 supply-chain nodes mapped.
13 distinct tier-1 suppliers in Q1 2026
| WEST PHARMA | Ireland | 74 |
| NOVO NORDISK | Denmark | 46 |
| NOVO NORDISK 25N ADVANCED PHA | Denmark | 13 |
| AR RACKING SAU | Spain | 9 |
| AR RACKING SAU | Portugal | 6 |
| OPEREBRO SL | Portugal | 4 |
| BAUSCH STROEBEL SE | Germany | 3 |
| NOVO NORDISK LYNGBY | Denmark | 3 |
Share of Q1 2026 inbound shipments by source country
38 tier-2 + 169 tier-3 nodes mapped - sign up to see them.
Free Tarifflo account unlocks the complete tier 1 / 2 / 3 supplier graph, daily refresh, alerts, and sanctions + UFLPA monitoring on every shipment.